Watch Dr. Sayuk discuss bacterial imbalance and IBS-D , and treatment with XIFAXAN

Gregory S Sayuk, MD, MPH

Associate Professor of Medicine and Psychiatry

Associate Director, Fellowship Training Program

Washington University of St. Louis School of Medicine in St. Louis

Division of Gastroenterology

Watch Dr. Sayuk discuss his clinical experience treating patients with IBS-D

IBS-D, irritable bowel syndrome with diarrhea.

Watch Dr. Brenner explain the importance of recognizing and treating multiple symptoms of IBS-D

 

Watch Dr. Chang explain the role of dysbiosis in the pathophysiology of IBS-D

 

Watch Dr. Cash discuss the inclusion of XIFAXAN for IBS-D in the American College of Gastroenterology’s 2020 Clinical Guideline on Managing IBS

 

Watch a patient discuss the impact of IBS-D and see her reaction to hearing Dr. Oneto describe XIFAXAN for the first time

 

Watch Dr. Pimentel and Dr. Brenner present information on the gut microbiota and IBS-D

 

Watch Dr. Pimentel, Dr. Brenner and Joscelyn Greaves, MSN, APRN-CNP, discuss different approaches used to manage IBS-D

 

See why Dr. Pimentel, Dr. Brenner and Joscelyn Greaves, MSN, APRN-CNP, think XIFAXAN FIRST

 

Watch this video explanation of how XIFAXAN is believed to work.

 

Watch Dr. Moussa discuss diagnosing IBS-D and treating with XIFAXAN

 

Watch our latest consumer TV spot
for XIFAXAN

 

Watch Dr. Pimentel discuss his
approach to IBS-D diagnosis

 

Watch Dr. Pimentel discuss the efficacy and safety of XIFAXAN

 

Watch Dr. Pimentel discuss XIFAXAN dosing

 
SEE MORE
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.